Hyperhemolysis in the Setting of Mixed-Autoimmune Hemolytic Anemia: A Rare Complication of COVID-19.
LewisGale Medical Center
SARS-CoV-2, autoimmune hemolytic anemia, covid 19, hyperhemolysis syndrome; immune thrombocytopenia purpura, mixed autoimmune hemolytic anemia
Hemic and Lymphatic Diseases | Immune System Diseases | Internal Medicine | Virus Diseases
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human pathogen known for its predilection on the respiratory system. Herein, we present a unique case in which a patient developed hyperhemolysis in the setting of mixed autoimmune hemolytic anemia (AIHA) secondary to SARS-CoV-2. A 33-years-old male with a past medical history of resolved immune thrombocytopenic purpura (ITP) presented to the hospital with symptoms of jaundice after being infected with SARS-CoV-2. On admission, his Hgb was 12.5 g/dL. Lab results showed indirect bilirubin of 13 mg/dL, LDH at 759 U/L, haptoglobin
Publisher or Conference
Narula S, Winkle S, Brand K, et al. Hyperhemolysis in the Setting of Mixed-Autoimmune Hemolytic Anemia: A Rare Complication of COVID-19. Cureus. 2021;13(12):e20356. doi:10.7759/cureus.20356